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The rise of SARS CoV-2 virus, a respiratory disease known 
as COVID-19, has presented providers and patients with 
unprecedented challenges regarding the prevention of 
breast cancer. COVID-19 has significantly impacted pre-
ventative screenings, diagnostic tests and genetic counseling 
both nationally and worldwide. Given the widespread con-
cerns regarding employment, social distancing, and virus 
exposure risk, many patients have reduced motivation to be 
proactive in utilizing preventative services (Janda, 2020). 
Researchers have predicted that these delays in screening 
and diagnosis could lead to a significant increase in can-
cer-related deaths, displaying an urgent need to increase 
preventative measures and employ risk reduction methods 
for long-term care of breast cancer patients. Given that 
early diagnosis has a significant impact on breast cancer 
prognosis, an analysis of screening changes is essential in 
navigating diagnostic regulations in the pandemic envi-
ronment and assessing long-term repercussions of inter-
ruption of breast cancer diagnostics. 
Nationally, multiple studies have revealed that breast can-
cer screening rates decreased amidst the lockdown period 
of the COVID-19 pandemic. One cross sectional study 
reported a 51.8% decrease in average weekly number of 
newly diagnosed breast patients when comparing a base-
line period (January 6, 2019 to February 29, 2020) to the 
emergence of COVID-19 (March 1 to April 18, 2020) 
(Kaufman, 2020). Furthermore, a US based survey 
revealed 26.5% of 404 participants reported 
deferred or cancelled breast cancer 
service, of which the most commonly 
impacted type was mammogram, 
MRI, or ultrasound (Warner, 2020). 
The decreased screening rates are likely 
a result of both closures due to hospi-
tal COVID-19 regulations, as well as 
altered health seeking behaviors to avoid 
exposure to the virus. Researchers have 
estimated that delayed screening could 
lead to an excess of more than 30,000 can-
cer and multimorbidity deaths in the US, 
suggesting an urgent need to plan for post-
pandemic increases in cancer incidence and 
management (Lai, 2020).
The delay of breast cancer screening and follow-
up poses significant risks to long-term breast 
cancer management. Due to this emerging cri-
sis, frequent patient monitoring as well as indi-
vidualized follow-up plans are desperately needed. 
Increased utilization of telehealth modalities can ena-
ble improved communication and frequency of follow-up 
appointments and bolster the doctor-patient relationship, 
while still maintaining adequate viral transmission pre-
cautions. The incorporation of hospital-provided private 
transportation services for select patients could facilitate 
increased accessibility for necessary in-person appoint-
ments. Some studies have also suggested that patients may 
benefit from direct behavioral “nudging” from practition-
ers; for example, personalized reminders for screening 
scheduling or incentives for influenza/COVID-19 vacci-
nations during diagnostic testing appointments (Janda, 
2020). One study from Taiwan revealed a delayed decrease 
in screening at mobile mammography visits compared 
to hospital mammography, suggesting that utilization of 
mobile units could increase screening rates (Peng, 2020). 
While health providers can enable systemic changes to 
improve cancer screening access and patient monitoring, 
it is critical that they consider established risk stratification 
schema, such as the one created by the American College 
of Surgeons’ COVID-19 Breast Cancer Consortium, to 
properly organize follow-up appointments in particularly 
vulnerable populations.
It is essential for physicians and public health practition-
ers to recognize the ways in which existing cancer dispari-
ties could be exacerbated in the pandemic environment. 
The COVID-19 pandemic has disproportionately affected 
underserved and vulnerable populations, which may have 
additional barriers, such as work conflicts, changes in 
employment, and lack of daycare services for children, 
that hinder utilization of screening services during the 
pandemic (Carethers, 2020). Therefore, it is critical that 
health professionals create outreach programs that can 
incorporate extended screening hours, awareness for screen-
ing programs, and transportation to improve accessibility 
for these populations. As vaccination efforts increase and 
the public begins to resume regularly scheduled preven-
tative care, healthcare providers must not only look 
to improve cancer screenings, but 
also focus on reaching out to vul-
nerable populations with missed 
diagnostic tests to mitigate wors-
ened prognosis.
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